Publications
98 results found
Kenny LM, Lam EW-F, 2011, Review: lapatinib in metastatic colorectal cancer-another strategy for disease control?, Clin Adv Hematol Oncol, Vol: 9, Pages: 500-501, ISSN: 1543-0790
Kenny LM, Al-Nahhas A, Aboagye EO, 2011, Novel PET biomarkers for breast cancer imaging, NUCLEAR MEDICINE COMMUNICATIONS, Vol: 32, Pages: 333-335, ISSN: 0143-3636
- Author Web Link
- Cite
- Citations: 11
Murphy N, Broadhurst D, Ezyani WN, et al., 2011, Cross sectional study to identify normal ranges for D-Dimers in pregnancy, 30th Annual Meeting of the Society-for-Maternal-Fetal-Medicine, Publisher: MOSBY-ELSEVIER, Pages: S320-S321, ISSN: 0002-9378
Contractor KB, Challapalli A, Barwick T, et al., 2011, Use of [11C]choline PET-CT as a non invasive method for detecting pelvic lymph node status from prostate cancer and relationship with choline kinase expression, ISSN: 1078-0432
PURPOSE: To evaluate the accuracy and biological basis for [11C] choline-PET-CT in the nodal staging of high risk localised prostate cancer patients.EXPERIMENTAL DESIGN: Twenty eight patients underwent dynamic [11C] choline-PET-CT of the pelvis and lower abdomen prior to extended laparoscopic pelvic lymph node dissection (eLPL). The sensitivity and specificity of [11C]choline PET, [11C]choline PET-CT and MRI for nodal detection were calculated. Average and maximal standardized Uptake Values (SUVave, SUVmax) were compared with choline kinase alpha (CHKalpha) and Ki67 immunohistochemistry scores.RESULTS: 406 lymph nodes, in 26 patients, were assessable. 27 (6.7%) involved pelvic nodes at eLPL were detected in 9 patients. 17 out of the 27 involved nodes were sub-centimetre. The sensitivity and specificity on a per nodal basis were 18.5 % and 98.7%, 40.7% and 98.4 %, and 51.9% and 98.4% for MRI, [11C]choline PET and [11C]choline PET-CT, respectively. Sensitivity was higher for [11C]choline PET-CT compared with MRI (p=0.007). A higher nodal detection rate, including sub-centimetre nodes, was seen with [11C]choline PET-CT than MRI. Malignant lesions showed CHKalpha expression in both cytoplasm and nucleus. SUVave and SUVmax strongly correlated with CHKalpha staining intensity (r=0.68, p<0.0001 and r=0.63, p=0.0004, respectively). In contrast, Ki67 expression was generally low in all tumors. CONCLUSIONS: This study establishes the relationship between [11C]choline PET- CT uptake with choline kinase expression in prostate cancer and allows it to be used as a non-invasive means of staging pelvic lymph nodes, being highly specific and more sensitive than MRI including the detection of sub-centimetre disease.
Contractor KB, Kenny L, Stebbing J, et al., 2011, [18F]-3'deoxy-3'-Fluorothymidine Positron Emission Tomography and Breast Cancer Response to Docetaxel, ISSN: 1078-0432
PURPOSE: To establish biomarkers indicating clinical response to taxanes, we determined whether early changes in [18F]-3'deoxy-3'-fluorothymidine positron emission tomography (FLT-PET) can predict benefit from docetaxel therapy in breast cancer.EXPERIMENTAL DESIGN: This was a prospective unblinded study in 20 patients with AJCC stage II-IV breast cancer unresponsive to first-line chemotherapy or progressing on previous therapy. Individuals underwent a baseline dynamic FLT-PET scan followed by a scan two weeks after initiating the first or second cycle of docetaxel. PET variables were compared to anatomical response mid-therapy (after 3 cycles). RESULTS: Average and maximum tumor standardized uptake values at 60 min (SUV60,av and SUV60,max) normalized to body surface area ranged between 1.7 and 17.0, and 5.6 and 26.9 x 10-5 m2/mL, respectively. Docetaxel treatment resulted in a significant decrease in FLT uptake (p=0.0003 for SUV60,av and p=0.0002 for SUV60,max). Reduction in tumor SUV60,av was associated with target lesion size changes mid-therapy (Pearson R for SUV60,av=0.64; p=0.004) and predicted mid-therapy target lesion response (0.85 sensitivity and 0.80 specificity). Decreases in SUV60,av in responders were due at least in part, to reduced net intracellular trapping of FLT (rate constant Ki). Docetaxel significantly reduced Ki by 51.1% (+/-28.4%, p=0.0009).CONCLUSIONS: Changes in tumor proliferation assessed by FLT-PET early after initiating docetaxel chemotherapy can predict lesion response mid-therapy with good sensitivity warranting prospective trials to assess the ability to stop therapy in the event of non-FLT-PET response.
Contractor KB, Kenny LM, Stebbing J, et al., 2011, Biological basis of [11C]choline-positron emission tomography in patients with breast cancer: comparison with [18F]fluorothymidine positron emission tomography, ISSN: 1473-5628
OBJECTIVE: The biological significance of [C]choline (CHO) uptake in human tumours is unclear and probably linked to choline kinase-alpha (CHKalpha) expression and cell proliferation. We directly compared CHO with [F]fluorothymidine (FLT), an imaging biomarker of proliferation, by positron emission tomography (PET) in patients with breast cancer to investigate whether cell proliferation is an important determinant of CHO uptake. Furthermore, we evaluated CHKalpha and the Ki67-labelling index (LIKi67) in tumour biopsies. METHODS: Sequential CHO-PET and FLT-PET within the same imaging session were performed in 21 patients with oestrogen receptor (ER)-positive breast cancer (28 lesions). Average and maximum CHO standardized uptake values (SUV) at 60 min: SUV60,av, and SUV60,max, and the rate constant of net irreversible uptake, Ki, were compared with FLT uptake at 60 min: SUV60,av and SUV60,max. Biopsies were stained for CHKalpha and LIKi67 in eight cases. RESULTS: Tumours were equally visible on CHO-PET and FLT-PET imaging. Tumour CHO-PET strongly correlated with FLT imaging variables (Pearson's r=0.83; P<0.0001 for CHO-SUV60,max vs. FLT-SUV60,max). A statistically significant association was found between CHO-PET variables and categorical scores of cytoplasmic CHKalpha intensity and between FLT-PET and LIKi67 (P<0.05, one-way analysis of variance). CONCLUSION: Choline metabolism and proliferation as assessed by PET were correlated in ER-positive breast cancer, indicating that high CHO uptake is a measure of cellular proliferation in this setting. CHO uptake was also found to be related to cytoplasmic CHKalpha expression.
Hatt M, Rest CC-L, Aboagye EO, et al., 2010, Reproducibility of <SUP>18</SUP>F-FDG and 3′-Deoxy-3′-<SUP>18</SUP>F-Fluorothymidine PET Tumor Volume Measurements, JOURNAL OF NUCLEAR MEDICINE, Vol: 51, Pages: 1368-1376, ISSN: 0161-5505
- Author Web Link
- Cite
- Citations: 108
Kenny LM, Contractor KB, Hinz R, et al., 2010, Reproducibility of [<SUP>11</SUP>C]Choline-Positron Emission Tomography and Effect of Trastuzumab, CLINICAL CANCER RESEARCH, Vol: 16, Pages: 4236-4245, ISSN: 1078-0432
- Author Web Link
- Cite
- Citations: 41
Contractor KB, Challapalli A, Sharma R, et al., 2010, Determination of pelvic node status in patients with high-risk localized or locally advanced prostate cancer by [<SUP>11</SUP>c]choline PET-CT, JOURNAL OF CLINICAL ONCOLOGY, Vol: 28, ISSN: 0732-183X
English FA, Walsh SK, McCarthy FP, et al., 2010, Overactivity of poly(ADP-ribose) polymerase contributes to endothelial dysfunction in an animal model of pre-eclampsia, Publisher: WILEY-BLACKWELL PUBLISHING, INC, Pages: 625-625, ISSN: 1470-0328
Kenny L, Seckl MJ, 2010, Treatments for gestational trophoblastic disease, Expert Review of Obstetrics and Gynecology, Vol: 5, Pages: 215-225, ISSN: 1747-4108
Gestational trophoblastic disease (GTD) is a relatively rare but important group of benign and malignant disorders that affect women of child-bearing potential. Most cases are now diagnosed earlier than previously owing to advances in our knowledge of the disease and accuracy of ultrasonography, combined with the high analytical sensitivity of human chorionic gonadotrophin assays, although occasionally patients with metastases present at a late stage with life-threatening complications. Early diagnosis and referral to a specialist center for further management is vital so that patients can receive the optimal standard of care. Patients can be grouped into high-and low-risk categories using well-established prognostic scoring systems, enabling the minimum appropriate treatment to be recommended. Chemotherapy regimens for the disease are now well established, so that for the vast majority, GTD is a curable condition, and patients can be reassured that fertility is normally preserved. Regular follow-up by human chorionic gonadotrophin measurement following treatment is important for the detection of early relapse. Regimens for relapsed disease are usually successful, but need to be improved for the infrequent cases that develop multiple drug resistance. In this article the subtypes of GTD, rationale for treatment, surgery and drugs used in the condition are discussed. © 2010 Expert Reviews Ltd.
Gray KR, Contractor KB, Kenny LM, et al., 2010, Kinetic filtering of [<SUP>18</SUP>F]Fluorothymidine in positron emission tomography studies, PHYSICS IN MEDICINE AND BIOLOGY, Vol: 55, Pages: 695-709, ISSN: 0031-9155
- Author Web Link
- Cite
- Citations: 27
Kenny LM, Seckl MJ, 2010, Treatments for Gestational Trophoblastic Disease, Expert Review of Obstetrics & Gynecology, Vol: 2, Pages: 215-225
Gestational trophoblastic disease (GTD) is a relatively rare but important group of benign and malignant disorders that affect women of child-bearing potential. Most cases are now diagnosed earlier than previously owing to advances in our knowledge of the disease and accuracy of ultrasonography, combined with the high analytical sensitivity of human chorionic gonadotrophin assays, although occasionally patients with metastases present at a late stage with life-threatening complications. Early diagnosis and referral to a specialist center for further management is vital so that patients can receive the optimal standard of care. Patients can be grouped into high- and low-risk categories using well-established prognostic scoring systems, enabling the minimum appropriate treatment to be recommended. Chemotherapy regimens for the disease are now well established, so that for the vast majority, GTD is a curable condition, and patients can be reassured that fertility is normally preserved. Regular follow-up by human chorionic gonadotrophin measurement following treatment is important for the detection of early relapse. Regimens for relapsed disease are usually successful, but need to be improved for the infrequent cases that develop multiple drug resistance. In this article the subtypes of GTD, rationale for treatment, surgery and drugs used in the condition are discussed.
Kenny LM, Contractor K, Stebbing J, et al., 2009, Changes in [<SUP>18</SUP>F]Fluorothymidine Pharmacokinetics Following Capecitabine Treatment in Human Breast Cancer Detected by Positron Emission Tomography, 32nd Annual San Antonio Breast Cancer Symposium, Publisher: AMER ASSOC CANCER RESEARCH, Pages: 765S-765S, ISSN: 0008-5472
Kenny LM, Contractor KB, Stebbing J, et al., 2009, Altered Tissue 3′-Deoxy-3′-[<SUP>18</SUP>F]Fluorothymidine Pharmacokinetics in Human Breast Cancer following Capecitabine Treatment Detected by Positron Emission Tomography, CLINICAL CANCER RESEARCH, Vol: 15, Pages: 6649-6657, ISSN: 1078-0432
- Author Web Link
- Cite
- Citations: 47
Newsom-Davis TE, Kenny LM, Ngan S, et al., 2009, The promiscuous receptor, BJU INTERNATIONAL, Vol: 104, Pages: 1204-1207, ISSN: 1464-4096
- Author Web Link
- Cite
- Citations: 5
Contractor KB, Kenny LM, Stebbing J, et al., 2009, [<SUP>11</SUP>C]Choline Positron Emission Tomography in Estrogen Receptor-Positive Breast Cancer, CLINICAL CANCER RESEARCH, Vol: 15, Pages: 5503-5510, ISSN: 1078-0432
- Author Web Link
- Cite
- Citations: 39
Rosso L, Gray KR, Contractor KB, et al., 2009, New Method for Segmentation of Tumors from [18F] FLT PET Images using Predefined Kinetic Classes, EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, Vol: 36, Pages: S193-S193, ISSN: 1619-7070
Kenny LM, Coombes RC, Contractor K, et al., 2009, [11C]Choline-PET imaging of breast cancer., J Clin Oncol, Vol: 27
1110 Background: Molecular imaging techniques are increasingly being used in cancer diagnosis, staging, and assessment of response to treatment. This study sought to evaluate, for the first time, [(11)C]choline-PET in patients with breast cancer. The potential of [(11)C]choline-PET for differentiating tumours from normal tissue, correlation with molecular markers, determine its normal variability range, and finally the effect of trastuzumab on [(11)C]choline uptake in patients with breast cancer was investigated. METHODS: 21 patients with newly diagnosed and recurrent breast cancer AJCC stage II-IV were enrolled in the study, all of whom had a baseline dynamic [(11)C]choline-PET scan with arterial sampling. 14 patients had 2 [(11)C]choline-PET scans to examine reproducibility, and 7 had a scan after trastuzumab. Analysis of [(11)C]choline uptake was measured using SUV, Ki (irreversible retention), and IRF@60min (retention using spectral analysis). RESULTS: Breast tumour lesions were visualised by [(11)C]choline PET in all patients. The difference in tumour and non-tumour uptake were significant for SUV, Ki, and IRF@60 min (Wilcoxon p < 0.0001 for all parameters). [(11)C]choline uptake was reproducible in breast tumour lesions (r(2) = 0.945 for SUV, 0.894 for Ki, and 0.799 for IRF60). The metabolism analysis of arterial plasma samples in 19 patients showed that [(11)C]choline decreased rapidly post-injection such that at 60 mins the mean radioactivity in arterial plasma due to choline was 15.15 ± 2.16%.Early responses to trastuzumab were determined to be significant in 5 lesions which corresponded with 3 clinical responses. CONCLUSIONS: [(11)C]choline-PET is a promising imaging modality in breast cancer, and could play an important role for determining response to novel treatment strategies in vivo. No significant financial relationships to disclose.
Kenny LM, Coombes RC, Contractor K, et al., 2009, [11C]Choline-PET imaging of breast cancer, 45th Annual Meeting of the American-Society-of-Clinical-Oncology, Publisher: AMER SOC CLINICAL ONCOLOGY, ISSN: 0732-183X
Newsom-Davis T, Kenny L, Al-Shakarchi I, et al., 2009, Voodoo dolls and the cancer patient: patients do trust their doctors, QJM-AN INTERNATIONAL JOURNAL OF MEDICINE, Vol: 102, Pages: 311-319, ISSN: 1460-2725
- Author Web Link
- Cite
- Citations: 8
McParland BJ, Miller MP, Spinks TJ, et al., 2008, The biodistribution and radiation dosimetry of the Arg-Gly-Asp peptide 18F-AH111585 in healthy volunteers, Journal of Nuclear Medicine, Vol: 49, Pages: 1664-1667
We report the safety, biodistribution, and internal radiation dosimetry of a new PET tracer, (18)F-AH111585, a peptide with a high affinity for the alpha(v)beta(3) integrin receptor involved in angiogenesis. METHODS: PET scans of 8 healthy volunteers were acquired at time points up to 4 h after a bolus injection of (18)F-AH111585. (18)F activity in whole blood and plasma and excreted urine were measured up to 4 h after injection. In vivo (18)F activities in up to 12 source regions were determined from quantitative analysis of the images. The cumulated activities subsequently calculated were then used to determine the internal radiation dosimetry, including the effective dose. RESULTS: Injection of (18)F-AH111585 was well tolerated in all subjects, with no serious or drug-related adverse events reported. The main route of (18)F excretion was renal (37%), and the 3 highest initial uptakes were by liver (15%); combined walls of the small, upper large, and lower large intestines (11%); and kidneys (9%). The 3 highest absorbed doses were received by the urinary bladder wall (124 microGy/MBq), kidneys (102 microGy/MBq), and cardiac wall (59 microGy/MBq). The effective dose was 26 microGy/MBq. CONCLUSION: (18)F-AH111585 is a safe PET tracer with a dosimetry profile comparable to other common (18)F PET tracers.
McParland BJ, Miller MP, Spinks TJ, et al., 2008, The Biodistribution and Radiation Dosimetry of the Arg-Gly-Asp Peptide <SUP>18</SUP>F-AH111585 in Healthy Volunteers, JOURNAL OF NUCLEAR MEDICINE, Vol: 49, Pages: 1664-1667, ISSN: 0161-5505
- Author Web Link
- Cite
- Citations: 67
Kenny LM, Coombes RC, Oulie I, et al., 2008, Phase I trial of the positron-emitting Arg-Gly-Asp (RGD) peptide radioligand <SUP>18</SUP>F-AH111585 in breast cancer patients, JOURNAL OF NUCLEAR MEDICINE, Vol: 49, Pages: 879-886, ISSN: 0161-5505
- Author Web Link
- Cite
- Citations: 264
Waxman J, Kenny L, Ngan S, 2008, New treatments for kidney cancer - New treatments offer hope, but await regulatory approval in the UK, BMJ-BRITISH MEDICAL JOURNAL, Vol: 336, Pages: 681-682, ISSN: 1756-1833
Kenny L, Coombes RC, Vigushin DM, et al., 2007, Imaging early changes in proliferation at 1 week post chemotherapy:: a pilot study in breast cancer patients with 3′-deoxy-3′-[<SUP>18</SUP>F]fluorothymidine positron emission tomography, EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, Vol: 34, Pages: 1339-1347, ISSN: 1619-7070
- Author Web Link
- Cite
- Citations: 216
Kenny LM, Ngan S, Waxman J, 2007, 'Time, gentlemen, please' for watchful waiting in prostate cancer?, BJU INTERNATIONAL, Vol: 100, Pages: 244-246, ISSN: 1464-4096
- Author Web Link
- Cite
- Citations: 1
Kenny LM, Aboagye E, Cohen PS, et al., 2007, Imaging of angiogenesis in metastatic breast cancer by positron emission tomography (PET) using [18F]AH11585, an [18F]- labeled alphaVbeta3 (αvβ3) peptide, Publisher: AMER SOC CLINICAL ONCOLOGY, ISSN: 0732-183X
Kenny L, 2007, Tbc., Clin Oncol (R Coll Radiol), Vol: 19, Pages: S6-S6, ISSN: 0936-6555
Kenny LM, Coombes RC, Al-Nahhas A, et al., 2006, A feasibility study of [<SUP>11</SUP>C]choline for the molecular imaging of human breast cancer <i>in vivo</i> using positron emission tomography (PET)., 42nd Annual Meeting of the American-Society-of-Clinical-Oncology, Publisher: AMER SOC CLINICAL ONCOLOGY, Pages: 31S-31S, ISSN: 0732-183X
This data is extracted from the Web of Science and reproduced under a licence from Thomson Reuters. You may not copy or re-distribute this data in whole or in part without the written consent of the Science business of Thomson Reuters.